Two oral presentations and eight posters feature Kriya's technology and manufacturing platforms that support its diverse pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases

Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Los Angeles, CA, May 16-20, 2023.

Kriya’s abstracts include two oral presentations and eight posters on its core technology and manufacturing platforms as well as its diverse pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.

“We are excited to share updates as we continue to advance our diverse pipeline of gene therapies,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya. “Our team has made significant progress in areas critical to the development, manufacturing, and characterization of gene therapies, and we look forward to presenting at this year's ASGCT."

The presentations include:

Oral Presentations:

Title: Analysis of Mechanisms Driving Improved Adeno-Associated Vector Production by the Addition of Small Molecules

Presenter: Nicholas Dietrich, Ph.D.

Session Date/Time: May 17 at 4:00 p.m. PT

Location: Concourse Hall 152 & 153

Abstract number: 47

Title: A Rapid, Serotype Specific Approach to AAV Formulation Development

Presenter: Robert Damitz, Ph.D.

Session Date/Time: May 18 at 2:00 p.m. PT

Location: Concourse Hall 150 & 151

Abstract number: 111

Poster Presentations:

Title: Sensitivity of AAV to Chemical and Physical Changes from Different Degradation Pathways

Presenter: Robert Damitz, Ph.D.

Session Date/Time: May 17 at 12:00 p.m. PT

Abstract number: 401

Title: Transcriptomic Profiling of Glycogen Storage Disease Type IX G2 Mouse Liver and Matched Plasma to Identify Biomarkers for Gene Therapy

Presenter: Sasha Makohon-Moore, Ph.D.

Session Date/Time: May 17 at 12:00 p.m. PT

Abstract number: 640

Title: Durability of AAV-Mediated Phenotypic Correction of Very Long-Chain Acyl-Coa Dehydrogenase (VLCAD) Deficiency in Mice

Presenter: Pilar Prentiss, M.S.

Session Date/Time: May 18 at 12:00 p.m. PT

Abstract number: 1156

Title: Optimizing Viral Genome Titer Methods: A Case Study on Improving Titer Accuracy Using ITR

Presenter: Rosalie Bateson

Session Date/Time: May 18 at 12:00 p.m. PT

Abstract number: 1232

Title: AAV Mediated Expression of a Chimeric Ion Channel in Combination with its Ligand Varenicline Demonstrates a Dose Response Improvement in Pain Hypersensitivity in a Rat Model of Trigeminal Pain

Presenter: Rosemarie Roeloffs, Ph.D.

Session Date/Time: May 19 at 12:00 p.m. PT

Abstract number: 1292

Title: Automated Monitoring, Analytics, and Machine-Learning for Improved Large Scale AAV Vector Production

Presenter: Mark Miller, Ph.D.

Session Date/Time: May 19 at 12:00 p.m. PT

Abstract number: 1302

Title: A Cell-Based Potency Method to Assess the Impact of Forced Degradation Methods on AAV Drug Product

Presenter: Lakmini Wasala, Ph.D.

Session Date/Time: May 19 at 12:00 p.m. PT

Abstract number: 1361

Title: Development of Adeno-Associated Virus Producer Cell Lines by Small Molecule Inducible Expression of Packaging Genes

Presenter: Nicholas Dietrich, Ph.D.

Session Date/Time: May 19 at 12:00 p.m. PT

Abstract number: 1580

About Kriya Therapeutics

Kriya Therapeutics, Inc. is a biopharmaceutical company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases. For more information, please visit www.kriyatx.com and follow on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502006156/en/

Our team has made significant progress in areas critical to the development, manufacturing, and characterization of gene therapies, and we look forward to presenting at this year's ASGCT.